Jennerich, Ann L
Downey, Lois
Goss, Christopher H
Kapnadak, Siddhartha G
Pryor, Joseph B
Ramos, Kathleen J
Funding for this research was provided by:
Cystic Fibrosis Foundation Therapeutics (LONG17A0)
Article History
Received: 12 January 2023
Accepted: 24 March 2023
First Online: 30 March 2023
Declarations
:
: This project was approved by the institutional review board at the University of Washington (STUDY00012301) and was performed in accordance with relevant guidelines and regulations. The need for written informed consent was waived by the institutional review board at the University of Washington due to the retrospective nature of the study.
: Not applicable.
: Dr. Jennerich reports grants from NIH NHLBI, grants from Cystic Fibrosis Foundation Therapeutics, Inc., during the conduct of the study. Dr. Goss reports grants from Cystic Fibrosis Foundation, grants from European Commission, grants from NIH (NHLBI), grants from NIH (NIDDK and NCRR), during the conduct of the study; personal fees from Gilead Sciences, personal fees from Novartis, grants from NIH, grants from FDA, other from Boehringer Ingelheim, other from Vertex Pharmaceuticals, outside the submitted work. Dr. Ramos reports grants from CHEST Foundation in partnership with Vertex Pharmaceuticals, during the conduct of the study; grants from Cystic Fibrosis Foundation, grants from National Institutes of Health, outside the submitted work. Ms. Downey, and Drs. Kapnadak and Pryor have nothing to disclose.